Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 10751321 
Hedges JC, et al. (2000) Phosphorylation of caldesmon by ERK MAP kinases in smooth muscle. Am J Physiol Cell Physiol 278, C718-26 10751321
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S789-p - Caldesmon (human)
Orthologous residues
Caldesmon (human): S789‑p, Caldesmon iso2 (human): S560‑p, Caldesmon iso3 (human): S554‑p, Caldesmon iso4 (human): S534‑p, Caldesmon iso6 (human): S559‑p, Caldesmon (mouse): S764‑p, Caldesmon iso5 (mouse): S526‑p, Caldesmon (rat): S527‑p, Caldesmon (rabbit): S529‑p, Caldesmon (chicken): S749‑p, Caldesmon (cow): S531‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  myocyte
 Cellular systems studied:  primary cells
 Species studied:  dog
 Comments:  tracheal myocytes
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (mouse)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ACh increase
PD98059 ACh inhibit treatment-induced increase
SB203580 ACh no effect upon treatment-induced increase
PDGF increase
PD98059 PDGF inhibit treatment-induced increase
SB203580 PDGF no effect upon treatment-induced increase
carbachol increase
AF-DX 116 carbachol inhibit treatment-induced increase
4-DAMP carbachol inhibit treatment-induced increase

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  myocyte
 Cellular systems studied:  primary cells
 Species studied:  dog
 Comments:  tracheal myocytes
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ACh increase
PD98059 ACh inhibit treatment-induced increase
PDGF increase
PD98059 PDGF inhibit treatment-induced increase

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  myocyte
 Cellular systems studied:  primary cells
 Species studied:  dog
 Comments:  tracheal myocytes
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ACh increase
PD98059 ACh inhibit treatment-induced increase
PDGF increase
PD98059 PDGF inhibit treatment-induced increase

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  myocyte
 Cellular systems studied:  primary cells
 Species studied:  dog
 Comments:  tracheal myocytes
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ACh increase
PD98059 ACh inhibit treatment-induced increase
PDGF increase
PD98059 PDGF inhibit treatment-induced increase

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  myocyte
 Cellular systems studied:  primary cells
 Species studied:  dog
 Comments:  tracheal myocytes
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ACh increase
PD98059 ACh inhibit treatment-induced increase
PDGF increase
PD98059 PDGF inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.